MCID: CLL014
MIFTS: 45

Cll/sll

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Cll/sll

MalaCards integrated aliases for Cll/sll:

Name: Cll/sll 12 15
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:6354
NCIt 50 C27911
SNOMED-CT 68 399607007
UMLS 73 C1302547

Summaries for Cll/sll

Disease Ontology : 12 A chronic lymphocytic leukemia that is characterized by the presence of immature lymphocytes in the blood and bone marrow and/or in the lymph nodes.

MalaCards based summary : Cll/sll, also known as chronic lymphocytic leukemia/small lymphocytic lymphoma, is related to leukemia, chronic lymphocytic and mantle cell lymphoma, and has symptoms including fatigue An important gene associated with Cll/sll is ZAP70 (Zeta Chain Of T Cell Receptor Associated Protein Kinase 70), and among its related pathways/superpathways are HTLV-I infection and DNA Damage Response. The drugs rituximab and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include b cells, lymph node and bone marrow, and related phenotypes are Decreased TP53 mRNA expression and hematopoietic system

Related Diseases for Cll/sll

Diseases related to Cll/sll via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 27.5 ATM CCND1 CD38 CD5 PAX5 TP53
2 mantle cell lymphoma 26.7 ATM CCND1 CD5 MME PAX5 SOX11
3 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.3
4 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.3
5 leukemia, chronic lymphocytic 2 10.5
6 leukemia 10.5
7 lymphoma 10.5
8 leukemia, b-cell, chronic 10.5
9 cd45 deficiency 10.5 CD5 ZAP70
10 epidural neoplasm 10.5 CD5 TP53
11 myxosarcoma 10.5 ATM TP53
12 non-proliferative fibrocystic change of the breast 10.5 CCND1 TP53
13 necrotizing sialometaplasia 10.5 CD5 TP53
14 oral leukoplakia 10.5 CCND1 TP53
15 prostate lymphoma 10.3 CD5 SOX11
16 hidradenocarcinoma 10.3 CCND1 TP53
17 mutagen sensitivity 10.3 CCND1 TP53
18 keratocystic odontogenic tumor 10.3 CCND1 TP53
19 tracheal lymphoma 10.3 CD5 MME
20 fallopian tube adenocarcinoma 10.3 MME TP53
21 cervical carcinosarcoma 10.3 MME TP53
22 nodular lymphocyte predominant hodgkin lymphoma 10.3 CCND1 PAX5
23 pre-malignant neoplasm 10.3 CCND1 TP53
24 waldenstrom macroglobulinemia 10.2 PAX5 ZAP70
25 adenosarcoma 10.2 MME TP53
26 breast benign neoplasm 10.2 MME TP53
27 intravascular large b-cell lymphoma 10.2 CD5 MME
28 thoracic benign neoplasm 10.2 MME TP53
29 mixed cell type cancer 10.2 MME TP53
30 gastrointestinal system benign neoplasm 10.2 CCND1 TP53
31 synchronous bilateral breast carcinoma 10.1 ATM CCND1 TP53
32 intestinal benign neoplasm 10.1 CCND1 TP53
33 lung lymphoma 10.1 CD5 PAX5
34 splenic marginal zone lymphoma 10.1 CD5 PAX5
35 malignant leydig cell tumor 10.0 MME PAX5
36 lymphoplasmacytic lymphoma 9.9 CD5 PAX5 SLC35B2
37 renal cell carcinoma, papillary, 1 9.9 ATM MME TP53
38 plasma protein metabolism disease 9.9 CD38 CD5
39 penile cancer 9.9 CCND1 TP53
40 peripheral t-cell lymphoma 9.9 CD5 MME TP53
41 diffuse large b-cell lymphoma 9.9 CD5 MME TP53
42 bare lymphocyte syndrome, type i 9.8 MME ZAP70
43 marginal zone b-cell lymphoma 9.8 CD5 MME SLC35B2
44 composite lymphoma 9.8 CD5 PAX5 SOX11
45 endometrial stromal sarcoma 9.8 CCND1 MME TP53
46 lymphoma, mucosa-associated lymphoid type 9.7 CCND1 CD5 MME
47 encapsulated thymoma 9.7 CD38 MME
48 leukemia, acute lymphoblastic 3 9.7 MME PAX5 TP53
49 invasive malignant thymoma 9.7 CD38 MME
50 acute lymphocytic leukemia 9.7 MME PAX5 TP53

Graphical network of the top 20 diseases related to Cll/sll:



Diseases related to Cll/sll

Symptoms & Phenotypes for Cll/sll

UMLS symptoms related to Cll/sll:


fatigue

GenomeRNAi Phenotypes related to Cll/sll according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased TP53 mRNA expression GR00389-S-5 8.62 ATM TP53

MGI Mouse Phenotypes related to Cll/sll:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.86 PAX5 SOX11 TP53 ATM ZAP70 CCND1
2 immune system MP:0005387 9.81 PAX5 SOX11 TP53 ATM ZAP70 CCND1
3 endocrine/exocrine gland MP:0005379 9.8 SOX11 TP53 ATM ZAP70 CCND1 CD38
4 integument MP:0010771 9.5 SOX11 TP53 ATM ZAP70 CCND1 CD5
5 normal MP:0002873 9.1 PAX5 SOX11 TP53 ZAP70 CCND1 CD5

Drugs & Therapeutics for Cll/sll

Drugs for Cll/sll (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
2
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1 21679-14-1, 75607-67-9 30751
3 Alkylating Agents Phase 3,Phase 2,Phase 1
4 Antibodies Phase 3,Phase 2,Phase 1
5 Immunoglobulins Phase 3,Phase 2,Phase 1
6 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
7 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
8 Antirheumatic Agents Phase 3,Phase 2,Phase 1
9 Antimetabolites Phase 2, Phase 3,Phase 1
10 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
11 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
12 Anti-Infective Agents Phase 3,Phase 2,Phase 1
13 Anti-HIV Agents Phase 3,Phase 1
14 Anti-Retroviral Agents Phase 3,Phase 1
15 Bendamustine Hydrochloride Phase 3,Phase 2,Phase 1
16 Antiviral Agents Phase 3,Phase 2,Phase 1
17
Tenofovir Phase 3 147127-20-6 464205
18 Reverse Transcriptase Inhibitors Phase 3
19 Nucleic Acid Synthesis Inhibitors Phase 3
20 tyrosine Nutraceutical Phase 3,Phase 1,Phase 2
21
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 32326 21704
22
Pentostatin Approved, Investigational Phase 2 53910-25-1 40926 439693
23
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
24
Adenosine Approved, Investigational Phase 2,Phase 1 58-61-7 60961
25
alemtuzumab Approved, Investigational Phase 2,Phase 1 216503-57-0
26
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
27
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
28
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
29
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
30
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
31
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
32
Allopurinol Approved Phase 2 315-30-0 2094
33
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
34
Busulfan Approved, Investigational Phase 2 55-98-1 2478
35
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
36
Pyrimethamine Approved, Investigational, Vet_approved Phase 1, Phase 2 58-14-0 4993
37
Melphalan Approved Phase 2 148-82-3 4053 460612
38
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
39
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
40
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
41
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
42
nivolumab Approved Phase 2,Phase 1 946414-94-4
43
Idelalisib Approved Phase 2 870281-82-6
44
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
45
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
46
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
47
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
48
leucovorin Approved, Nutraceutical Phase 1, Phase 2 58-05-9 143 6006
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
50
motexafin gadolinium Investigational Phase 1, Phase 2 156436-89-4 12047567

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
2 A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL Recruiting NCT03336333 Phase 3 BGB-3111;Bendamustine;Rituximab
3 Tenofovir to Prevent HBV Reactivation Recruiting NCT02186574 Phase 3 Tenofovir disoproxil;Placebo Oral Tablet
4 A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) Active, not recruiting NCT02004522 Phase 3 IPI-145 (duvelisib);Ofatumumab
5 A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Active, not recruiting NCT01578707 Phase 3 ofatumumab;ibrutinib
6 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
7 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07 Enrolling by invitation NCT02049515 Phase 3 IPI-145 (duvelisib);Ofatumumab
8 Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies Terminated NCT00714259 Phase 2, Phase 3 Fludarabine
9 Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Unknown status NCT01024010 Phase 2 pentostatin;cyclophosphamide
10 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis Completed NCT00001586 Phase 2 Fludarabine phosphate
11 Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed NCT00974233 Phase 2 Bendamustine;Rituximab;Lenalidomide
12 Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Completed NCT01002755 Phase 2 Lenalidomide;Ofatumumab
13 Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Completed NCT01515176 Phase 1, Phase 2 Dinaciclib
14 A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia Completed NCT01403636 Phase 2 SAR245409
15 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00280241 Phase 2 Fludarabine;Cyclophosphamide;Rituximab
16 Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00193518 Phase 2 Arsenic Trioxide
17 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Completed NCT01217749 Phase 1, Phase 2 PCI-32765;ofatumumab
18 Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Completed NCT00201682 Phase 1, Phase 2 Etanercept;Rituximab
19 Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT00193466 Phase 2 Rituximab;Fludarabine;CAMPTH-1H
20 Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00439231 Phase 2 Lenalidomide
21 Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT00290004 Phase 1, Phase 2 motexafin gadolinium
22 Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00873457 Phase 2 perifosine
23 Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT00935792 Phase 1, Phase 2 alemtuzumab;everolimus
24 Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT00669318 Phase 2 pentostatin;sargramostim
25 Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00090090 Phase 2 Elsamitrucin
26 Safety of PCI-32765 in Chronic Lymphocytic Leukemia Completed NCT01105247 Phase 1, Phase 2 PCI-32765
27 Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting NCT02225275 Phase 2 Lenalidomide;Obinutuzumab
28 Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL Recruiting NCT03379051 Phase 1, Phase 2 Venetoclax;Umbralisib;Ublituximab
29 Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Recruiting NCT02337829 Phase 2 acalabrutinib;acalabrutinib
30 A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting NCT02514083 Phase 2 Ibrutinib;Fludarabine
31 Study to Evaluate Safety and Preliminary Efficacy of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS) Recruiting NCT02639910 Phase 2 Idelalisib;Venetoclax
32 Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NCT01066663 Phase 1, Phase 2 pyrimethamine
33 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NCT03204188 Phase 2 Ibrutinib;Fludarabine;Pembrolizumab
34 Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL Recruiting NCT01754857 Phase 2 Bendamustine;Rituximab;Lenalidomide
35 Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Recruiting NCT03010358 Phase 1, Phase 2 Entospletinib
36 Safety, PK, PD, and Antitumor Activity of SNS-062 (Vecabrutinib) in B Lymphoid Cancers Recruiting NCT03037645 Phase 1, Phase 2 SNS-062
37 Phase 1/2A Dose Escalation Study in CLL, SLL or NHL Recruiting NCT01994382 Phase 1, Phase 2 Cerdulatinib (PRT062070)
38 Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Recruiting NCT03045328 Phase 2 Ibrutinib;Venetoclax
39 Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma Recruiting NCT03370185 Phase 2 Duvelisib
40 Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Recruiting NCT03041636 Phase 2 Ruxolitinib
41 Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) Recruiting NCT03128879 Phase 2 Venetoclax;Ibrutinib;Allopurinol
42 Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Recruiting NCT02420912 Phase 2 Nivolumab;Ibrutinib
43 Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Recruiting NCT02988466 Phase 2 GVHD Prophylaxis
44 A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NCT02406742 Phase 1, Phase 2 CC-122;CC-122;Ibrutinib;CC-122;Obinutuzumab
45 High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Recruiting NCT03128359 Phase 2 Busulfan;Cyclophosphamide;Fludarabine Phosphate;Melphalan Hydrochloride;Mycophenolate Mofetil;Tacrolimus
46 Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Active, not recruiting NCT01497496 Phase 2 High Dose Methylprednisolone (HDMP);Ofatumumab;Lenalidomide
47 Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Active, not recruiting NCT01496976 Phase 2 High Dose Methylprednisolone (HDMP);Ofatumumab;Lenalidomide
48 Efficacy and Safety of BGB-3111 in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Active, not recruiting NCT03206918 Phase 2 BGB-3111
49 Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT02518555 Phase 2 Ibrutinib
50 Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT01351896 Phase 2 Lenalidomide

Search NIH Clinical Center for Cll/sll

Genetic Tests for Cll/sll

Anatomical Context for Cll/sll

MalaCards organs/tissues related to Cll/sll:

41
B Cells, Lymph Node, Bone Marrow, Bone, T Cells, Myeloid, Neutrophil

Publications for Cll/sll

Articles related to Cll/sll:

(show top 50) (show all 78)
# Title Authors Year
1
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
2
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness. ( 29762141 )
2018
3
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. ( 29444501 )
2018
4
Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study. ( 29289901 )
2018
5
Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting simultaneously with acquired hemophilia and warm autoimmune hemolytic anemia. ( 28670081 )
2017
6
Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in a Warthin Tumor: Case Report and Literature Review. ( 28978260 )
2017
7
An unusual case of chronic diarrhea: chronic lymphocytic leukemia/small lymphocytic lymphoma with colorectal involvement. ( 28511955 )
2017
8
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. ( 28103725 )
2017
9
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. ( 28592889 )
2017
10
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28073846 )
2017
11
Two Distinct BCL2 Rearrangements, Each Observed in 2 Independent Subclones, Evolving from a Founder Clone with Trisomy 12 in a Unique Case of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28514780 )
2017
12
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. ( 28373262 )
2017
13
Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length. ( 28718694 )
2017
14
Lymphomatoid papulosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma: 3 cases. ( 28569995 )
2017
15
CLL/SLL with initial presentation as a longstanding cutaneous plaque: A rare case. ( 27147484 )
2016
16
Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K). ( 26740820 )
2016
17
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 27324214 )
2016
18
Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 25795422 )
2015
19
Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma. ( 25120048 )
2015
20
Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication. ( 24738974 )
2015
21
Flow cytometric analysis of lymphoid enhancer-binding factor 1 in diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 25596247 )
2015
22
The spectrum of kidney pathology in B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma: a 25-year multicenter experience. ( 25811382 )
2015
23
Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression. ( 24673649 )
2014
24
Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands. ( 25038918 )
2014
25
Hyperdiploidy in CLL/SLL: A Rare Cytogenetic Event Associated with Poor Prognosis. ( 26030621 )
2014
26
A Unique Case of Concurrent Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma and Lymphomatoid Papulosis in the Same Biopsy. ( 25382820 )
2014
27
Expression of PIM1 protein in chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 24547709 )
2014
28
Peripheral T-cell lymphomas with cytotoxic phenotype in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 24418862 )
2014
29
Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. ( 22944294 )
2013
30
Efficacy of oral fludarabine in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 23545817 )
2013
31
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 23645694 )
2013
32
Leukemia Cutis Coexisting With Dermatofibroma as the Initial Presentation of B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 23974225 )
2013
33
Symptomatic BK virus reactivation following fludarabine, cyclophosphamide and rituximab chemotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 23987823 )
2013
34
Sweet syndrome in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: curious lymphocyte/neutrophil fluctuations. ( 24385834 )
2013
35
Case study interpretation-New Orleans: case 4. Richter syndrome characterized by diffuse large B cell lymphoma in the context of prior chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 23283841 )
2013
36
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 23508840 )
2013
37
Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 23382602 )
2013
38
Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. ( 23136257 )
2013
39
CLL/SLL diagnosed in an adolescent. ( 24281971 )
2013
40
Richter Syndrome With Follicular Colonization of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Cells Mimicking Follicular Lymphoma. ( 24249845 )
2013
41
Novel FGFR3 rearrangement t(4;22)(p16;q11.2) in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 23584505 )
2013
42
Use of Positron Emission Tomography-Computerized Tomography (PET-CT) in the Management of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). ( 24286263 )
2013
43
Collision of chronic lymphocytic leukemia/small lymphocytic lymphoma and melanoma. ( 23923507 )
2013
44
Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression. ( 22706868 )
2012
45
TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice. ( 22711886 )
2012
46
Composite chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma are biclonal lymphomas: a report of two cases. ( 22431543 )
2012
47
Cyclin D2 is overexpressed in proliferation centers of chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 21790895 )
2011
48
Chronic lymphocytic leukemia/small lymphocytic lymphoma with pancytopenia and chylothorax. ( 21421106 )
2011
49
Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. ( 21685909 )
2011
50
Rare association of chronic lymphocytic leukemia/small lymphocytic lymphoma, ANCAs, and pauci-immune crescentic glomerulonephritis. ( 20974512 )
2011

Variations for Cll/sll

Expression for Cll/sll

Search GEO for disease gene expression data for Cll/sll.

Pathways for Cll/sll

Pathways related to Cll/sll according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1 12.16 ATM CCND1 TP53
2
Show member pathways
12.11 ATM CCND1 TP53
3 12.09 ATM CCND1 TP53
4
Show member pathways
12.07 ATM CCND1 TP53
5
Show member pathways
11.97 ATM CCND1 TP53
6 11.96 ATM PAX5 TP53
7 11.86 ATM CCND1 TP53
8 11.82 ATM CCND1 TP53
9 11.64 CD38 CD5 MME
10 11.6 ATM CCND1 TP53
11 11.48 CD38 CD5 MME
12 11.13 ATM CCND1 TP53
13 11 ATM TP53
14 10.98 ATM CCND1 TP53
15
Show member pathways
10.84 ATM TP53
16 10.71 ATM TP53
17 10.65 CD38 CD5 MME PAX5
18 10.64 ATM CCND1 TP53

GO Terms for Cll/sll

Biological processes related to Cll/sll according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to gamma radiation GO:0071480 9.32 ATM TP53
2 response to X-ray GO:0010165 9.26 CCND1 TP53
3 determination of adult lifespan GO:0008340 9.16 ATM TP53
4 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
5 replicative senescence GO:0090399 8.8 ATM MME TP53

Sources for Cll/sll

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....